Group 1 - The top three companies with the highest short positions as of August 1 are WuXi AppTec (02359), CATL (03750), and Luye Pharma (02186), with short ratios of 20.99%, 15.26%, and 13.94% respectively [1][2] - The companies with the largest absolute increase in short positions are ZTE Corporation (00763), Jinxin Fertility (01951), and Vanke Enterprises (02202), with increases of 2.92%, 2.49%, and 2.44% respectively [1][2] - The companies with the largest absolute decrease in short positions are UBTECH Robotics (09880), Kelai Ying (06821), and Mingyuan Cloud (00909), with decreases of -2.34%, -1.30%, and -1.28% respectively [1][3] Group 2 - The top ten companies with the highest short ratios include WuXi AppTec (02359) at 20.99%, CATL (03750) at 15.26%, and Luye Pharma (02186) at 13.94% [2] - The companies with the most significant increase in short ratios include ZTE Corporation (00763) from 8.47% to 11.39%, Jinxin Fertility (01951) from 7.94% to 10.43%, and Vanke Enterprises (02202) from 9.81% to 12.26% [2] - The companies with the most significant decrease in short ratios include UBTECH Robotics (09880) from 3.97% to 1.63%, Kelai Ying (06821) from 7.30% to 6.01%, and Mingyuan Cloud (00909) from 4.33% to 3.04% [3][4]

8月6日，绿叶制药(02186)盘中下跌5.13%，截至10:17，报3.88元/股，成交1.19亿元。 绿叶制药集团有限公司主要在全球最大和增长最快的四个治疗领域（肿瘤科、中枢神经系统、心血管系 统及消化与代谢）进行创新药品的开发、生产、推广及销售，产品组合包括超过30种产品，覆盖全球80 个以上国家和地区。关键经营数据显示，2021年，公司产品销售覆盖全国30个省、自治区和直辖市，通 过约1000名销售和营销人员以及约1780家经销商网络，产品销往19330多家医院，同时在国际市场覆盖 80个国家或地区。 截至2024年年报，绿叶制药营业总收入60.61亿元、净利润4.72亿元。 本文源自：金融界 作者：行情君 ...

Core Insights - The report highlights significant changes in the shareholding ratios of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Increased Shareholding Ratios - The companies with the largest increases in shareholding ratios include: - Hang Seng China Enterprises (02828) with an increase of 4.29%, reaching a holding ratio of 19.02% [1][2] - Dongjiang Environmental (00895) with an increase of 2.08%, reaching a holding ratio of 42.98% [1][2] - Meizhong Jiahe (02453) with an increase of 2.02%, reaching a holding ratio of 32.46% [1][2] - Over the last five trading days, the top gainers in shareholding ratios were: - Hang Seng China Enterprises (02828) with an increase of 11.75% [5] - Changfei Optical Fiber (06869) with an increase of 7.15%, reaching a holding ratio of 45.78% [5] - Zhengzhou Bank (06196) with an increase of 3.95%, reaching a holding ratio of 51.58% [5] Group 2: Decreased Shareholding Ratios - The companies with the largest decreases in shareholding ratios include: - Shandong Molong (00568) with a decrease of 3.32%, holding 58.15% [3][4] - Kanglong Chemical (03759) with a decrease of 1.21%, holding 54.05% [3][4] - Green Leaf Pharmaceutical (02186) with a decrease of 1.09%, holding 39.33% [3][4] - Over the last five trading days, the top decliners in shareholding ratios were: - Shandong Xinhua Pharmaceutical (00719) with a decrease of 5.14%, holding 42.62% [6] - Guolian Minsheng (01456) with a decrease of 2.30%, holding 52.59% [6] - Dongfang Electric (01072) with a decrease of 2.06%, holding 40.71% [6] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in shareholding ratios included: - Hang Seng China Enterprises (02828) with an increase of 18.02%, holding 19.02% [8] - Changfei Optical Fiber (06869) with an increase of 17.40%, holding 45.78% [8] - Junda Co., Ltd. (02865) with an increase of 14.19%, holding 27.55% [8] - The companies with the largest decreases in shareholding ratios over the last 20 trading days included: - Shijiazhuang Octagon (09676) with a decrease of 13.12%, holding 9.51% [9] - Marco Digital Technology (01942) with a decrease of 9.35%, holding 43.30% [9] - Tigermed (03347) with a decrease of 8.65%, holding 58.37% [9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 绿叶制药集团有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02186 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 | 本月 ...

Core Insights - Green Leaf Pharmaceutical (02186) has announced the completion of the first subject enrollment in a Phase I clinical study for its innovative drug LY03021 in China, which is designed to treat depression [1][2] Group 1: Drug Mechanism and Development - LY03021 is a novel antidepressant that acts as a norepinephrine transporter (NET) and dopamine transporter (DAT) inhibitor, as well as a positive allosteric modulator of the GABA A receptor (GABAAR) [1] - The drug targets three mechanisms: NET, DAT, and GABAAR, aiming to enhance the balance of glutamate and GABA in the brain, thereby quickly exerting antidepressant effects [1][2] Group 2: Clinical Study Details - The Phase I clinical trial is a single-center, randomized, double-blind, placebo-controlled, dose-escalation study aimed at assessing the safety, tolerability, and pharmacokinetic characteristics of LY03021 in healthy subjects [2] - Non-clinical studies indicate that LY03021 significantly improves depressive symptoms in model animals within 24 hours of administration, with stable efficacy observed over a 21-day treatment period [2] Group 3: Safety Profile - LY03021 demonstrates a favorable safety profile, with a no-observed-adverse-effect level (NOAEL) exceeding 50 times the effective dose [2]

Core Viewpoint - Green Leaf Pharmaceutical Group announced the completion of the first subject enrollment in the Phase I clinical study of its self-developed innovative drug LY03021 in China, which is intended for the treatment of depression [1] Company Summary - LY03021 is classified as a first-class innovative drug and functions as a norepinephrine transporter (NET)/dopamine transporter (DAT) inhibitor and a positive allosteric modulator of the GABA A receptor [1] - The drug is specifically aimed at addressing the treatment of depression, indicating a strategic focus on mental health therapeutics [1]

Group 1 - The company, Green Leaf Pharmaceutical (stock code: 02186), announced the issuance of 21,167,800 ordinary shares through the conversion of its 5.85% convertible bonds maturing in 2025, valued at 10 million USD [1] - The conversion price for the shares is set at HKD 3.672 per share [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) announced the issuance of 21,167,800 ordinary shares by converting $10 million of 5.85% convertible bonds due in 2025 at an exchange price of HKD 3.672 per share [1] Group 1 - The company is converting $10 million of its 5.85% convertible bonds into ordinary shares [1] - The conversion price is set at HKD 3.672 per share [1] - A total of 21,167,800 ordinary shares will be issued as a result of this conversion [1]

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02186 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | | 已發行股份總數 | | 於下列日期開始時的 ...

Group 1 - The top three companies with the highest short positions as of July 25 are WuXi AppTec (02359), CATL (03750), and Luye Pharma (02186), with short ratios of 23.32%, 16.32%, and 14.03% respectively [1][2] - The company with the largest absolute increase in short positions is Jinli Permanent Magnet (06680), with an increase of 3.23%, followed by Dongfang Electric (01072) and China Duty Free Group (01880) with increases of 2.55% and 2.52% respectively [1][2] - The companies with the largest absolute decrease in short positions include Dongfeng Motor Group (00489) with a decrease of -3.15%, followed by Jinxin Fertility (01951) and Ganfeng Lithium (01772) with decreases of -2.09% and -1.99% respectively [1][2] Group 2 - The top ten companies with the highest short ratios include WuXi AppTec (02359) at 23.32%, CATL (03750) at 16.32%, and Luye Pharma (02186) at 14.03% [2] - The companies with the most significant increases in short ratios include Jinli Permanent Magnet (06680) from 1.45% to 4.68%, Dongfang Electric (01072) from 6.15% to 8.70%, and China Duty Free Group (01880) from 2.68% to 5.20% [2] - The companies with the most significant decreases in short ratios include Dongfeng Motor Group (00489) from 7.32% to 4.17%, Jinxin Fertility (01951) from 10.03% to 7.94%, and Ganfeng Lithium (01772) from 13.66% to 11.67% [3]